Coronavirus Update: Ethics Considerations, Guidance and Resources.
It appears you're using Mirosoft Internet Explorer or an early version of Edge. To fully enjoy this website — and pretty much every modern website in existence — we suggest you upgrade to Chrome or Firefox. You'll be happier.
Aducanumab has just been approved by the Food and Drug Administration to slow the progress of Alzheimer’s disease. It is likely that many people who are candidates for the drug will no longer be competent to make their own health care decisions, and will be relying heavily on others to make the decision with them or for them.
June 7, 2021, was a bad day for science. That was the day the U.S. Food and Drug Administration approved aducanumab for the treatment of Alzheimer’s disease, even though a committee of its own selected experts recommended strongly against approval.
This year, CMS passed/promulgated a new final rule establishing, among other things, that death certificate data drawn from a database of the Centers for Disease Control and Prevention would be used to determine the number of eligible donors. While attractive as a “readily and publicly available” resource for estimating donor potential, using death certificate data to measure actual donor potential is dangerously flawed.
Time-limited trials offer I.C.U. patients and their families a sense of empowerment in the face of low odds.
Taking Steps Brattleboro is offering weekly Advance Care Planning Information Meetings via Zoom every Wednesday at 10am and 6pm. Learn more and sign up.
The pandemic is not over, but light is beginning to crest the horizon. Vaccination rates, especially among older adults and their caregivers, are rising. As we begin to relax physical distancing requirements on restaurants and professional sports, it’s time to urgently reconsider the severe restrictions imposed on nursing home residents.
An op-ed by Don Freeman of Taking Steps Brattleboro, a program of Brattleboro Area Hospice, reminding readers of the importance of completing an advance directive.
Hastings Center president Mildred Solomon discussed disability rights and bioethics, including COVID-related issues, during an interview on “Included: The Disability Equity Podcast.” Listen and find additional related resources.
As Covid-19 continues to plague the United States, insufficient attention has been paid to the role that incarcerated persons play in the persistence of this pandemic and the work that should be done to limit their infection and suffering.
As states continue to expand access to Covid-19 vaccination to prioritized groups, members of the public are observing system problems firsthand. Vaccine navigators have emerged as a response to complexity.
As students, professors, and practitioners of medicine, we know that teachable moments are often found outside the classroom walls. We have seen that Black and brown communities are disproportionately impacted by Covid-19. But juxtaposing these disparities with vaccination rates is even more disturbing. Fewer vaccines are going to Black people.
There have been some calls for a more pragmatic approach eschewing micromanaging distribution and instead focusing on speed and access. While there are indeed practical considerations supporting a more logistically streamlined system, we believe there are, more importantly, ethical reasons to prefer an approach that vaccinates more people more rapidly.
More Americans are writing end-of-life instructions as the pandemic renders such decisions less abstract. But are medical providers listening?
View the results of our Ethics Survey for Vermont & New Hampshire conducted in the summer of 2019.